Russia must make reparations for MH17, Australia says
The Strasbourg court on Wednesday found Russia failed to verify the target of a missile that shot down a Malaysia Airlines aircraft with 298 people on board over Ukraine's Donetsk region on July 17, 2014.
The ECHR also said that Moscow failed to protect the lives of those on board the Boeing 777, which was en route from Amsterdam to Kuala Lumpur when it was hit by an anti-aircraft missile fired by pro-Russian rebels.
All 298 people on board were killed, including 38 Australians, 96 Dutch nationals and four Germans. Russia denies responsibility for the incident.
"We welcome the European Court of Human Rights' ruling that Russia is responsible for the downing of Flight MH17," Wong said on X, calling it a "historic moment for the 298 victims and their loved ones".
In May, the council of the International Civil Aviation Organisation (ICAO) also found Russia responsible for the aircraft's downing under international air law, in a case brought by Australia and the Netherlands.
"This ruling follows the ICAO Council's decision in May that Russia is responsible and must negotiate with Australia and the Netherlands on full reparations," Wong said.
"We again call upon Russia to face up to its responsibility and make reparations for this horrific act."
The impact of the ECHR's decision is limited, as Russia does not recognise the court.
Two Russians and a Ukrainian were sentenced in absentia to life imprisonment by a Dutch court in 2022 for murder in 298 cases. Russia continues to deny any responsibility and refuses to extradite the men.
Russia was expelled from the Council of Europe following the 2022 invasion of Ukraine and is consequently no longer a member of the European Convention on Human Rights, which the court oversees.
However, the court - which is independent of the European Union - can still rule on incidents that occurred up to six months after expulsion.
Australian Foreign Minister Penny Wong has called for Russia to make reparations for the 2014 downing of Malaysia Airlines flight MH17, after the European Court of Human Rights found Moscow responsible for the tragedy.
The Strasbourg court on Wednesday found Russia failed to verify the target of a missile that shot down a Malaysia Airlines aircraft with 298 people on board over Ukraine's Donetsk region on July 17, 2014.
The ECHR also said that Moscow failed to protect the lives of those on board the Boeing 777, which was en route from Amsterdam to Kuala Lumpur when it was hit by an anti-aircraft missile fired by pro-Russian rebels.
All 298 people on board were killed, including 38 Australians, 96 Dutch nationals and four Germans. Russia denies responsibility for the incident.
"We welcome the European Court of Human Rights' ruling that Russia is responsible for the downing of Flight MH17," Wong said on X, calling it a "historic moment for the 298 victims and their loved ones".
In May, the council of the International Civil Aviation Organisation (ICAO) also found Russia responsible for the aircraft's downing under international air law, in a case brought by Australia and the Netherlands.
"This ruling follows the ICAO Council's decision in May that Russia is responsible and must negotiate with Australia and the Netherlands on full reparations," Wong said.
"We again call upon Russia to face up to its responsibility and make reparations for this horrific act."
The impact of the ECHR's decision is limited, as Russia does not recognise the court.
Two Russians and a Ukrainian were sentenced in absentia to life imprisonment by a Dutch court in 2022 for murder in 298 cases. Russia continues to deny any responsibility and refuses to extradite the men.
Russia was expelled from the Council of Europe following the 2022 invasion of Ukraine and is consequently no longer a member of the European Convention on Human Rights, which the court oversees.
However, the court - which is independent of the European Union - can still rule on incidents that occurred up to six months after expulsion.
Australian Foreign Minister Penny Wong has called for Russia to make reparations for the 2014 downing of Malaysia Airlines flight MH17, after the European Court of Human Rights found Moscow responsible for the tragedy.
The Strasbourg court on Wednesday found Russia failed to verify the target of a missile that shot down a Malaysia Airlines aircraft with 298 people on board over Ukraine's Donetsk region on July 17, 2014.
The ECHR also said that Moscow failed to protect the lives of those on board the Boeing 777, which was en route from Amsterdam to Kuala Lumpur when it was hit by an anti-aircraft missile fired by pro-Russian rebels.
All 298 people on board were killed, including 38 Australians, 96 Dutch nationals and four Germans. Russia denies responsibility for the incident.
"We welcome the European Court of Human Rights' ruling that Russia is responsible for the downing of Flight MH17," Wong said on X, calling it a "historic moment for the 298 victims and their loved ones".
In May, the council of the International Civil Aviation Organisation (ICAO) also found Russia responsible for the aircraft's downing under international air law, in a case brought by Australia and the Netherlands.
"This ruling follows the ICAO Council's decision in May that Russia is responsible and must negotiate with Australia and the Netherlands on full reparations," Wong said.
"We again call upon Russia to face up to its responsibility and make reparations for this horrific act."
The impact of the ECHR's decision is limited, as Russia does not recognise the court.
Two Russians and a Ukrainian were sentenced in absentia to life imprisonment by a Dutch court in 2022 for murder in 298 cases. Russia continues to deny any responsibility and refuses to extradite the men.
Russia was expelled from the Council of Europe following the 2022 invasion of Ukraine and is consequently no longer a member of the European Convention on Human Rights, which the court oversees.
However, the court - which is independent of the European Union - can still rule on incidents that occurred up to six months after expulsion.
Australian Foreign Minister Penny Wong has called for Russia to make reparations for the 2014 downing of Malaysia Airlines flight MH17, after the European Court of Human Rights found Moscow responsible for the tragedy.
The Strasbourg court on Wednesday found Russia failed to verify the target of a missile that shot down a Malaysia Airlines aircraft with 298 people on board over Ukraine's Donetsk region on July 17, 2014.
The ECHR also said that Moscow failed to protect the lives of those on board the Boeing 777, which was en route from Amsterdam to Kuala Lumpur when it was hit by an anti-aircraft missile fired by pro-Russian rebels.
All 298 people on board were killed, including 38 Australians, 96 Dutch nationals and four Germans. Russia denies responsibility for the incident.
"We welcome the European Court of Human Rights' ruling that Russia is responsible for the downing of Flight MH17," Wong said on X, calling it a "historic moment for the 298 victims and their loved ones".
In May, the council of the International Civil Aviation Organisation (ICAO) also found Russia responsible for the aircraft's downing under international air law, in a case brought by Australia and the Netherlands.
"This ruling follows the ICAO Council's decision in May that Russia is responsible and must negotiate with Australia and the Netherlands on full reparations," Wong said.
"We again call upon Russia to face up to its responsibility and make reparations for this horrific act."
The impact of the ECHR's decision is limited, as Russia does not recognise the court.
Two Russians and a Ukrainian were sentenced in absentia to life imprisonment by a Dutch court in 2022 for murder in 298 cases. Russia continues to deny any responsibility and refuses to extradite the men.
Russia was expelled from the Council of Europe following the 2022 invasion of Ukraine and is consequently no longer a member of the European Convention on Human Rights, which the court oversees.
However, the court - which is independent of the European Union - can still rule on incidents that occurred up to six months after expulsion.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AU Financial Review
an hour ago
- AU Financial Review
Trade stand-off continues as US drug tariffs loom
Australia's pharmaceutical benefits scheme is not up for negotiation, says the federal government in the face of ramped-up US threats to triple the price of foreign medicines. In a continuation of his erratic approach to trade policy, President Donald Trump says taxes on drug imports could be announced as soon as the end of the month, with eventual tariff rates of up to 200 per cent. 'We're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff,' Trump said. Australia's Pharmaceutical Benefits Scheme, under which the government negotiates medicine prices with manufacturers before subsidising them for patients, is reportedly in the crosshairs of US pharmaceutical companies lobbying the White House. The Albanese government has flatly refused any negotiation on the PBS. 'Obviously, they are being lobbied, as other US presidents have been for many years by the US big pharma industry, which wants not just Australia's scheme but other schemes like it around the world ... they want that freed up,' federal health minister Mark Butler said on Wednesday. 'They want to see their profits increased. That's been the case for decades and decades.' The PBS is crucial to ensure equitable and affordable access to medicines, according to Royal Australian College of GPs president Michael Wright. 'We should be proud of the prime minister and treasurer's steadfast support for maintaining the PBS, regardless of external pressure.' But complaints about such pricing schemes are common across the industry and include Australian medicine manufacturers, says Melbourne University research fellow Joe Carrello. 'They argue the increasing costs it takes to investigate and run trials and bring a new drug to market aren't keeping up with what the return is, given what the government is willing to pay,' Dr Carrello said. Dr Carrello, who helps evaluate medicines proposed for the PBS after their approval by the Therapeutic Goods Administration, said there could be consequences to a relatively small market like Australia negotiating such lean prices. 'The fear is some US companies may decide against launching new drugs in Australia because comparatively, they're not going to get a good price,' he said. In the US, where a relatively free-market approach has been favoured, drug prices are almost three times higher than in 33 comparable income countries, according to RAND research. Australians have an average life expectancy of 83.2 years, compared to 77.4 years in the US, World Bank data shows. 'Without the PBS, we'd see people losing access to affordable medications and an increased spend per person on average but it wouldn't be evenly distributed,' Dr Carrello said.
West Australian
an hour ago
- West Australian
Trade stand-off continues as US drug tariffs loom
Australia's pharmaceutical benefits scheme is not up for negotiation, says the federal government in the face of ramped-up US threats to triple the price of foreign medicines. In a continuation of his erratic approach to trade policy, President Donald Trump says taxes on drug imports could be announced as soon as the end of the month, with eventual tariff rates of up to 200 per cent. "We're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff," Mr Trump said. Australia's Pharmaceutical Benefits Scheme, under which the government negotiates medicine prices with manufacturers before subsidising them for patients, is reportedly in the crosshairs of US pharmaceutical companies lobbying the White House. The Albanese government has flatly refused any negotiation on the PBS. "Obviously, they are being lobbied, as other US Presidents have been for many years by the US big pharma industry, which wants not just Australia's scheme but other schemes like it around the world ... they want that freed up," federal health minister Mark Butler said on Wednesday. "They want to see their profits increased. That's been the case for decades and decades." The PBS is crucial to ensure equitable and affordable access to medicines, according to Royal Australian College of GPs president Michael Wright. "We should be proud of the prime minister and treasurer's steadfast support for maintaining the PBS, regardless of external pressure." But complaints about such pricing schemes are common across the industry and include Australian medicine manufacturers, says Melbourne University research fellow Joe Carrello. "They argue the increasing costs it takes to investigate and run trials and bring a new drug to market aren't keeping up with what the return is, given what the government is willing to pay," Dr Carrello told AAP. Dr Carrello, who helps evaluate medicines proposed for the PBS after their approval by the Therapeutic Goods Administration, said there could be consequences to a relatively small market like Australia negotiating such lean prices. "The fear is some US companies may decide against launching new drugs in Australia because comparatively, they're not going to get a good price," he said. In the US, where a relatively free-market approach has been favoured, drug prices are almost three times higher than in 33 comparable income countries, according to RAND research. Australians have an average life expectancy of 83.2 years, compared to 77.4 years in the US, World Bank data shows. "Without the PBS, we'd see people losing access to affordable medications and an increased spend per person on average but it wouldn't be evenly distributed," Dr Carrello said. In a submission to a Productivity Commission inquiry, pharmaceutical giant Pfizer criticised the PBS's assessment process, claiming it under-accounted for drug and vaccine benefits over multiple budget cycles and missed broader social benefits. "Over the last decade, while the total PBS spend has increased, the proportion of the PBS that funds innovative medicines has seen minimal growth," Pfizer wrote in its submission. "This means, as a proportion of GDP, the government's expenditure on innovative medicines is going backwards." Federal treasurer Jim Chalmers has joined the health minister in ruling out any changes to the PBS in US trade negotiations. "This Albanese Labor government is about strengthening the PBS in the interests of our people, not weakening it in the interests of American multinationals," he recently said. As for Australian drug producers, the federal government was still weighing the impacts of the proposed tariffs on Australian exports, which were worth $2.2 billion in 2024. "(President Trump) indicated there was a long lead time, a long period where he'd be considering this possible step," Dr Chalmers said. That lead time was cut by a matter of months this week, in a sign the United States' push may be turning to a shove.
Perth Now
an hour ago
- Perth Now
Trade stand-off continues as US drug tariffs loom
Australia's pharmaceutical benefits scheme is not up for negotiation, says the federal government in the face of ramped-up US threats to triple the price of foreign medicines. In a continuation of his erratic approach to trade policy, President Donald Trump says taxes on drug imports could be announced as soon as the end of the month, with eventual tariff rates of up to 200 per cent. "We're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff," Mr Trump said. Australia's Pharmaceutical Benefits Scheme, under which the government negotiates medicine prices with manufacturers before subsidising them for patients, is reportedly in the crosshairs of US pharmaceutical companies lobbying the White House. The Albanese government has flatly refused any negotiation on the PBS. "Obviously, they are being lobbied, as other US Presidents have been for many years by the US big pharma industry, which wants not just Australia's scheme but other schemes like it around the world ... they want that freed up," federal health minister Mark Butler said on Wednesday. "They want to see their profits increased. That's been the case for decades and decades." The PBS is crucial to ensure equitable and affordable access to medicines, according to Royal Australian College of GPs president Michael Wright. "We should be proud of the prime minister and treasurer's steadfast support for maintaining the PBS, regardless of external pressure." But complaints about such pricing schemes are common across the industry and include Australian medicine manufacturers, says Melbourne University research fellow Joe Carrello. "They argue the increasing costs it takes to investigate and run trials and bring a new drug to market aren't keeping up with what the return is, given what the government is willing to pay," Dr Carrello told AAP. Dr Carrello, who helps evaluate medicines proposed for the PBS after their approval by the Therapeutic Goods Administration, said there could be consequences to a relatively small market like Australia negotiating such lean prices. "The fear is some US companies may decide against launching new drugs in Australia because comparatively, they're not going to get a good price," he said. In the US, where a relatively free-market approach has been favoured, drug prices are almost three times higher than in 33 comparable income countries, according to RAND research. Australians have an average life expectancy of 83.2 years, compared to 77.4 years in the US, World Bank data shows. "Without the PBS, we'd see people losing access to affordable medications and an increased spend per person on average but it wouldn't be evenly distributed," Dr Carrello said. In a submission to a Productivity Commission inquiry, pharmaceutical giant Pfizer criticised the PBS's assessment process, claiming it under-accounted for drug and vaccine benefits over multiple budget cycles and missed broader social benefits. "Over the last decade, while the total PBS spend has increased, the proportion of the PBS that funds innovative medicines has seen minimal growth," Pfizer wrote in its submission. "This means, as a proportion of GDP, the government's expenditure on innovative medicines is going backwards." Federal treasurer Jim Chalmers has joined the health minister in ruling out any changes to the PBS in US trade negotiations. "This Albanese Labor government is about strengthening the PBS in the interests of our people, not weakening it in the interests of American multinationals," he recently said. As for Australian drug producers, the federal government was still weighing the impacts of the proposed tariffs on Australian exports, which were worth $2.2 billion in 2024. "(President Trump) indicated there was a long lead time, a long period where he'd be considering this possible step," Dr Chalmers said. That lead time was cut by a matter of months this week, in a sign the United States' push may be turning to a shove.
